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requirements for JAK2 activation in the
nucleus and the process guiding plasma
membrane-bound active JAK2 to the
nucleus. However, basal phosphorylation
of histone H3Y41 would hint at some
redundancy in this pathway that may not
require JAK2.
It has been apparent for some time that
STAT5 cannot be the only major tran-
scriptional effector of JAK2 and other
substrates of this kinase have been char-
acterized with various impact on gene
expression. The identification of histone
H3Y41 as a target of JAK2-dependent
HP1a regulation adds a new dimension
to the field of JAK2 biology. These find-
ings will help to unravel some of the
dynamics within the intricate signaling
networks required for early hematopoi-
esis. As correctly pointed out by Dawson
et al. (2009), the role of the HP1a binding
region in nucleosome mobility and
stability as well as that of HP1a itself in
mitotic recombination may explain some
of the genomic instability associated
with malignancies containing active JAK2
(Fernandes et al., 2009; Plo et al., 2008).
Nevertheless, it seems likely that other
factors might regulate HP1a and the
degree of JAK2 requirement is not entirely
clear. It will need to be carefully deter-
mined whether these novel interactions
of JAK2 with histone H3Y41 open up
new opportunities for targeted thera-
peutic approaches that may benefit
patients with hematologic neoplasms or
other malignancies that involve deregu-
lated JAK2 activity. Finally, it is possible
that other members of the Janus kinase
family (JAK1, JAK3, and TYK2) may have
analogous functions in the nucleus and
that should be examined.
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Genetic alternations resulting in constitutive stabilization of b-catenin and altered transcription of b-catenin/
TCF-regulated genes are found in many cancers. A recent Nature paper offers insights into the role of
tankyrase in regulating the Wnt/b-catenin pathway and suggests that compounds targeting tankyrase’s
poly-ADP-ribosylation (PARsylation) activity may hold promise for cancer therapy.Defects in conserved signaling pathways
are well known to play key roles in the
origins and behavior of essentially all
cancers. Mutations affecting the Wnt
signaling pathway underlie the pathogen-
esis of cancers, including upwards of
80%–90% of colorectal cancers (CRCs)
(MacDonald et al., 2009). TheWnt proteins
are a conserved family of secreted mole-
culeswith pleiotropic andcontext-specific
effects on cells (MacDonald et al., 2009).
In the canonical or b-catenin-dependent366 Cancer Cell 16, November 3, 2009 ª200Wnt pathway, Wnts regulate the level and
subcellular localization of b-catenin. In
the absence of an activating Wnt signal,
glycogen synthase kinase 3b (GSK3b)
collaborates with the AXIN and APC
(adenomatous polyposis coli) proteins
andother factors to phosphorylateb-cate-
nin at its amino (N)-terminal domain. The
phosphorylated b-catenin is recognized
andubiquitinatedby a complex containing
a b-transducin repeat-containing protein
(bTrCP), then degraded by the protea-9 Elsevier Inc.some. Wnt binding to the Frizzled-low
density lipoprotein-related protein (LRP)-
5/6coreceptor complexon thecell surface
inhibits the AXIN/GSK3b complex and
stabilizes the free pools of b-catenin. In
the nucleus, b-catenin can bind to T cell
factor (TCF) transcriptional regulators
along with other cofactors and modulate
transcription of various genes. Mutational
mechanisms with major contributing roles
in stabilizing b-catenin in human cancer
include inactivation of APC or AXIN1 or
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Previewsactivating (oncogenic) mutations in b-cat-
enin’s N-terminal domain (MacDonald
et al., 2009), all of which lead to altered
transcription of b-catenin/TCF-regulated
genes in the absence of exogenous Wnt
signals.
In spite of the great progress in under-
standing the Wnt pathway and its muta-
tions in cancers, successes have been
limited with respect to illuminating strate-
gies for therapeutic targeting of this
pathway. A recent paper in the journal
Nature not only offers important new
insights into proteins regulating Wnt
signaling but also further supports the
approach to antagonize b-catenin levels
and localization via small molecules
(Huanget al., 2009).Huangandcolleagues
used a high throughput screen to identify
a small molecule XAV939 that interfered
with Wnt-stimulated transcription. They
found that XAV9393 blocked Wnt-stimu-
lated accumulation of b-catenin by in-
creasing the levels of the AXIN1 and
AXIN2 proteins. Subsequent work by the
authorsestablished thatXAV939 regulates
AXIN levels via inhibition of tankyrases 1
and 2 (TNKS1 and TNKS2), both of which
aremembersof thepoly(ADP-ribose) poly-
merase (PARP) protein family (Hsiao and
Smith, 2008). TNKS1/2 bind directly to
AXIN proteins and appear to regulate
AXIN levels via poly-ADP-ribosylation
(PARsylation) andubiquitination. Evidence
that the TNKS proteins regulate the Wnt
pathway in physiological settings was
also obtained, via a Wnt signaling-depen-
dent zebrafish model of fin regeneration.
Moreover, XAV939 was shown to inhibit
growth of the APC-defective CRC cell
line DLD-1, and the antiproliferative effect
of XAV939 was abrogated when AXIN1/2
levels were depleted in these cells by
siRNA approaches. An independent study
from Chen and colleagues had uncovered
a compound termed IWR-1 in a high
throughput screen that acted by an
unknown mechanism to stabilize AXIN
and block b-catenin accumulation (Chen
et al., 2009). The Huang et al. group
showed that the IWR-1 compound, like
XAV393, exerted its effects via inhibition
of TNKS1/2 PARsylation activity.
Notwithstanding the elegance and
sophisticationof the study, does thepaper
herald the emergence of a new era for the
therapeutic targeting of the Wnt pathway
in cancer? At the risk of being viewed as
a skeptic, I would offer the short answer‘‘maybe.’’ The papers of Huang et al. and
Chen et al. offer further compelling
support for earlier work that showed both
APC and AXIN function as key scaffold
proteins for b-catenin but AXIN protein
levels are limiting under physiological
conditions (MacDonald et al., 2009, and
references therein). Another notable
advance is that the enzymatic function of
TNKS1/2 enhances their candidacies as
‘‘druggable’’ targets in the Wnt pathway.
Todate,muchof the research on inhibiting
the Wnt pathway has focused on inter-
fering with protein-protein interactions,
either Wnt-receptor interactions or
b-catenin binding to TCF proteins or other
nuclear cofactors, such as CREB-binding
protein (CBP) (Barker and Clevers, 2007,
and references therein). Besides the
obvious challenges associated with iden-
tifying small molecules that potently
interfere with protein-protein interactions,
constitutive b-catenin dysregulation in
cancer arises most frequently from
mutational defects downstream of Wnt-
receptor interactions and thus would be
minimally affected by ligand-receptor
antagonists. Transcription factors and
cofactors often interact with multiple
nuclear proteins; compounds that antago-
nize their interaction with b-catenin might
also interfere with their interaction with
other critical proteins. Given this back-
ground, TNKS1/2 joins a small list of
downstream Wnt pathway factors with
presumptive enzymatic function, such as
the chromatin remodeling-associated
factor Brg1 (Barker and Clevers, 2007)
and the kinases CDK8 and TNIK (Firestein
et al., 2008; Mahmoudi et al., 2009), which
could perhaps be targeted in cancer cells
for therapeutic effect.
The utility of compounds, like XAV939,
that stabilize AXIN1/2 would presumably
be limited to cancer cells with upstream
ligand-receptor defects or APC defects,
or perhaps also those with defects in one
of the two, but not both, AXIN proteins.
Cancer cells that express a mutant onco-
genic b-catenin protein would presum-
ably be resistant to AXIN stabilization.
Moreover, a major assumption underlying
cancer therapy with compounds that
stabilize AXIN proteins and in turn antago-
nize b-catenin is that advanced cancer
cells with b-catenin defects are highly
dependent on continued dysregulation of
b-catenin. To date, the limited data to
implicate dysregulated b-catenin as a crit-Cancer Cell 16,ical factor in the continued growth and
survival of advanced cancer cells reveal
differences from one cell line to another
(Kim et al., 2002, and references therein).
At this point, the argument that antago-
nizing dysregulated b-catenin function
in advanced cancer cells will have broad
and profound therapeutic effects is far
from certain. The availability of com-
pounds like XAV939 and IWR-1 should
help to advance knowledge of the range
and types of cancers and precancers
that might be amenable to b-catenin
antagonism and possible mechanisms
for its resistance.
Various unsettled issues with respect to
the action of XAV939 on cancer cells
include uncertainties about whether its
growth inhibitory action reflects effects of
AXIN stabilization on b-catenin versus
other AXIN-interacting proteins. Elevated
levels of AXIN1 have been shown to
potently inhibit thegrowthofHCT116cells,
which express a mutant b-catenin but are
not dependent on it for growth and survival
(Satoh et al., 2000; Kim et al., 2002). More-
over, AXIN proteins may even have posi-
tive roles in cancer progression in some
settings, such as in epithelial-mesen-
chymal transition via stabilization of the
Snail1 transcriptional repressor (Yook
et al., 2006). There is also much to be
learned about the role of TNKS1/2 function
in normal and cancer cells. TNKS proteins
are evolutionarily conserved and function
in telomere length regulation and sister
telomerecohesion,GLUT4vesicle translo-
cation, and possibly also mitotic spindle
pole regulation (Hsiao and Smith, 2008).
As such, targeting of TNKS1/2 might be
expected to have varied effects on cells.
Notably, inhibition of TNKS1 resulted in
synthetic lethal effects in cells with
BRCA1 or BRCA2 defects, due apparently
to exacerbation of the centrosomeamplifi-
cation phenotype associated with BRCA
deficiency (McCabe et al., 2009).
An implied promise of the enormous
progress achieved in our understanding
of the molecular pathogenesis of cancer
is that a plethora of new therapeutic
targets will be revealed. The new findings
on TNKS1/2 function in regulating AXIN
and the potential of the TNKS1/2 proteins
as therapeutic targets highlight the power
of innovative chemical genetics and pro-
teomics approaches as well as concep-
tual challenges that need to be addressed
before directed targeting of cancer cellsNovember 3, 2009 ª2009 Elsevier Inc. 367
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Previewswith Wnt pathway defects becomes a
reality.
REFERENCES
Barker, N., and Clevers, H. (2007). Nat. Rev. Drug
Discov. 5, 997 1014.
Chen, B., Dodge, M.E., Tang, W., Lu, J., Ma, Z.,
Fan, C.W., Wei, S., Hao, W., Kilgore, J., Williams,
N.S., et al. (2009). Nat. Chem. Biol. 5, 100 107.
Firestein, R., Bass, A.J., Kim, S.Y., Dunn, I.F.,
Silver, S.J., Guney, I., Freed, E., Ligon, A.H.,
Vena, N., Ogino, S., et al. (2008). Nature 455,
547 551.368 Cancer Cell 16, November 3, 2009 ª20Hsiao, S.J., and Smith, S. (2008). Biochime 90,
83 92.
Huang, S.M., Mishina, Y.M., Liu, S., Cheung, A.,
Stegmeier, F., Michaud, G.A., Charlat, O., Wiel
lette, E., Zhang, Y., Wiessner, S., et al. (2009).
Nature 461, 614 620.
Kim, J.S., Crooks, H., Foxworth, A., and Waldman,
T. (2002). Mol. Cancer Ther. 1, 1355 1359.
MacDonald, B.T., Tmai, K., and He, X. (2009).
Dev. Cell 17, 9 25.
Mahmoudi, T., Li, V.S.W., Ng, S.S., Taouatas, N.,
Vries, R.G.J., Mohammed, S., Heck, A.J., and09 Elsevier Inc.Clevers, H. (2009). EMBO J. 10.1038/emboj.
2009.285.
McCabe, N., Cerone, M.A., Ohishi, T., Seimiya, H.,
Lord, C.J., and Ashworth, A. (2009). Oncogene 28,
1465 1470.
Satoh, S., Daigo, Y., Furukawa, Y., Kato, T., Miwa,
N., Nishiwaki, T., Kawasoe, T., Ishiguro, H., Fujita,
M., Tokino, T., et al. (2000). Nat. Genet. 24,
245 250.
Yook, J.I., Li, X.Y., Ota, I., Hu, C., Kim, H.S., Kim,
N.H., Cha, S.Y., Ryu, J.K., Choi, Y.J., Kim, J.,
et al. (2006). Nat. Cell Biol. 8, 1398 1406.
